Three core trends emerge as pivotal forces driving the healthcare sector forward: strategic responses to economic uncertainty, the accelerated growth in AI investments, and the groundbreaking advancements in next-generation medications. Together, these trends do not merely represent shifts within the health sector; they signal a critical tipping point, one that demands adaptability, foresight, and an unwavering focus on innovation to navigate the future of health care.
“Over his impressive career, John has successfully scaled technology solutions for the life sciences industry,” said Beth Beghou, CEO of Beghou Consulting. “I know he is as enthusiastic as we are about helping companies develop agile and patient-centric commercialization models.”
Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.
Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.